EBR Systems (ASX:EBR) said that the US Centers for Medicare & Medicaid Services has proposed the approval of a new technology add-on payment for the company's WiSE cardiac resynchronization therapy system for the treatment of heart failure, according to a Tuesday filing with the Australian bourse.
If approved, the maximum add-on payment will be 65% of the device cost in addition to standard Medicare payments and will be effective for three years starting Oct. 1, the filing said.
The company plans to seek similar support for outpatient use, the filing added.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.